For immediate release: Monday, October 23, 2013
Boston, MA – A major collaborative research effort involving scientists at Harvard School of Public Health (HSPH), Brigham and Women’s Hospital (BWH), and Harvard University has uncovered a novel signal mechanism that controls how fat storage in the liver can communicate with fat burning in skeletal muscle.
Especially striking is that 1) this ‘conversation’ involves one nuclear receptor-controlling gene expression in the liver influencing another nuclear receptor in muscle, 2) this circuit is influenced by day-night cycles, and 3) the research team identified a specific circulating lipid molecule that plays the role of messenger between liver and muscle.
The study will appear in the October 24, 2013 issue of Nature.
Maintaining the overall balance of energy involves the ability to use fatty acids to make lipids, a process known as de novo lipogenesis that occurs in the liver. Fatty acids are also burned to generate energy, as occurs in skeletal muscle. Given differences in the need for an organism to burn fatty acids while awake versus asleep, prior work has suggested that lipogenesis, and the genes involved in these pathways, vary in circadian (day-night) patterns.
Programs for energy use and storage are regulated by nuclear receptors—transcription factors that control entire programs of genes. PPAR delta regulates lipogenesis and PPAR alpha governs fatty acid oxidation. Disordered lipogenesis and fatty acid oxidation are important contributors to obesity-associated problems like fatty liver and diabetes.
In the study, researchers demonstrate that when the liver makes fat through lipogenesis, a signal is sent to skeletal muscle cells to burn fat through fatty acid oxidation. The fat-making process in the liver is controlled by PPAR delta, while the fat-burning process in muscle is controlled by PPAR alpha. Using a process of isolating lipid molecules appearing in plasma, the researchers uncovered a specific lipid molecule, namely a phospholipid that is released by the liver into the blood stream under the control of PPAR delta and serves as the signal to PPAR alpha in skeletal muscle.
Mice lacking PPAR delta in the liver lost production of this molecule while mice lacking PPAR alpha no longer responded to this signal. This pathway between liver and muscle also exhibited a circadian rhythm. Moreover, high-fat feeding altered these processes, consistent with other data implicating obesity effects on normal day-night cycles.
“This finding uncovers a joint effort of the liver and muscle to maintain balanced fat production and burning, a biological process tailored to match the body’s energy demands and maximize fuel-burning efficiencies during the day versus night,” said Chih-Hao Lee, HSPH associate professor of genetics and complex diseases, corresponding senior author.
“It is increasingly evident that metabolic responses and diseases influenced by metabolic abnormalities, involve coordinated changes in organs like the liver and muscle,” said Jorge Plutzky, director of the BWH Vascular Disease Prevention Program, senior co-author. “By identifying a liver-to-muscle circuit involving fat storage and fatty acid oxidation, and a naturally occurring candidate molecule involved in directing these effects, this study highlights the nature of such integrated responses, and the evolving power of combining traditional experimental models in cells and pre-clinical models with profiling approaches like lipidomics.”
The researchers are now studying how this phospholipid is carried in the circulatory system and delivered to muscle. They hope the work generates greater understanding of normal metabolism in liver and muscle and provides new therapeutic opportunities to treat fatty liver, obesity, and diabetes.
The study was also led by co-first authors Sihao Liu, HSPH; Jonathan Brown, Brigham and Women’s Hospital; senior co-author, Alan Saghatelian, Harvard University; and senior co-author, Gokhan S. Hotamisligil, J.S. Simmons Professor of Genetics and Metabolism and chair, Department of Molecular Metabolism, HSPH.
This research was supported by the American Heart Association, American Diabetes Association, and National Institutes of Health (R01DK075046, R01HL048743, K08HL105678).
For more information:
Marge Dwyer
mhdwyer@hsph.harvard.edu
617.432.8416
Marjorie Montemayor-Quellenberg
Brigham and Women’s Hospital
mmontemayor-quellenberg@partners.org
617-534-2208
###
Harvard School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people’s lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at HSPH teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as the oldest professional training program in public health. For more information on the school visit: https://www.hsph.harvard.edu
Brigham and Women’s Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham’s medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation’s first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses’ and Physicians’Health Studies and the Women’s Health Initiative. For more information and resources, please visit BWH’s online newsroom.